DrugPatentWatch Database Preview
Hoffman-la Roche Company Profile
Email this page to a colleague
» See Plans and PricingUS Patents for Hoffman-la Roche
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffman-la Roche | PEGASYS | peginterferon alfa-2a | VIAL; SUBCUTANEOUS | 103964 | 001 | 2002-10-16 | 10,071,108 | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbann, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Par | 2033-09-11 | RX | search | |
| Hoffman-la Roche | PEGASYS | peginterferon alfa-2a | VIAL; SUBCUTANEOUS | 103964 | 001 | 2002-10-16 | 10,392,349 | NOVIRA THERAPEUTICS, INC. (Doylestown, PA) | 2034-01-16 | RX | search | |
| Hoffman-la Roche | PEGASYS | peginterferon alfa-2a | VIAL; SUBCUTANEOUS | 103964 | 001 | 2002-10-16 | 10,478,444 | Enterin, Inc. (Philadelphia, PA) | 2029-10-27 | RX | search | |
| Hoffman-la Roche | PEGASYS | peginterferon alfa-2a | VIAL; SUBCUTANEOUS | 103964 | 001 | 2002-10-16 | 10,537,580 | NOVIRA THERAPEUTICS, INC. (Doylestown, PA) | 2035-03-19 | RX | search | |
| Hoffman-la Roche | PEGASYS | peginterferon alfa-2a | VIAL; SUBCUTANEOUS | 103964 | 001 | 2002-10-16 | 10,596,173 | 2040-03-24 | RX | search | ||
| Hoffman-la Roche | PEGASYS | peginterferon alfa-2a | VIAL; SUBCUTANEOUS | 103964 | 001 | 2002-10-16 | 10,656,152 | ForSight Vision4, Inc. (South San Francisco, CA) | 2029-01-29 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
